Refine your search
Collections
Co-Authors
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Bairagi, V. A.
- Antioxidants Therapy in Cognitive Dysfunction Associated with Diabetes Mellitus: An Overview
Abstract Views :295 |
PDF Views:0
Authors
Affiliations
1 K.B.H.S.S.T's Institute of Pharmacy, Bhayagaon Road, Malegaon Camp, Malegaon, Dist. Nasik (MS), IN
1 K.B.H.S.S.T's Institute of Pharmacy, Bhayagaon Road, Malegaon Camp, Malegaon, Dist. Nasik (MS), IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 3, No 2 (2011), Pagination: 39-44Abstract
Diabetic complications, characterized by endothelial dysfunction. There is growing evidence that excess generation of highly reactive free radicals, largely due to hyperglycemia, causes oxidative stress. Overproduction free radicals result in vascular dysfunction, damage to cellular proteins, membrane lipids and nucleic acids. As our understanding of the mechanisms of free radical generation evolves, it is becoming clear that rather than merely scavenging reactive radicals, a more comprehensive approach aimed at preventing the generation of these reactive species as well as scavenging may prove more beneficial. Endogenous antioxidant defenses are both non-enzymatic (e.g., uric acid, glutathione, bilirubin, thiols, albumin, and nutritional factors, including vitamins and phenols) and enzymatic (e.g., the superoxide dismutase's, the glutathione peroxides [GSHPx], and catalyses). So that there is use of antioxidants must be used for future beneficial. Therefore, new strategies with classic as well as new antioxidants should be implemented, to prevent cognitive dysfunction associated with diabetes mellitus.Keywords
Diabetes Mellitus, Free Radical, Hyperglycemia, Antioxidants.References
- Jeanette SJ et al. Oxidative stress and the use of antioxidants in diabetes. Cardiovascular Diabetology. 2005; 10:1186-1475.
- Jarbas SR et al. (Pre)diabetes, brain aging and cognition. Biochimica Biophysica Acta. 2008; 10:1016.
- Pyorala K et al. Diabetes and atherosclerosis an epidemiologic view. Diabetes Metabol Rev. 2006; 3:463-524.
- Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999; 48:937-942.
- American Diabetes Association National diabetes fact sheet. 2002, [http://www.diabetes.org/diabetes-statistics.jsp].
- Giugliano D et al. Oxidative stress and diabetic vascular complications. Diabetes Care. 1996; 19:257-267.
- Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care. 2003; 26:1589-1596.
- Bruehla HO. Modifiers of cognitive function and brain structure in middle aged and elderly individuals with type 2 diabetes mellitus. Brain research. 2009; 48, 654-676.
- Abbatecola AM et al. Insulin resistance and executive dysfunction in older persons. J Am Geriatr Soc. 2004; 52:1713-1718.
- Alberti GD. Introduction to the metabolic syndrome. Eur Heart J. Suppl. 2005; 244-254.
- Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis?” Circulation. 2002; 105:2107-2111.
- Jha P, Flather M. The antioxidant vitamins and cardiovascular disease a critical review of epidemiologic and clinical trial data. Ann Intern Med. 2000; 123:860-872.
- Violi F, Micheletta F. How to select patient candidates for antioxidant treatment? Circulation. 2002; 106-195.
- Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998; 47:859-866.
- Haneda M, et al. Mitogen-activatedprotein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions:Diabetes. 2002; 46:847-853.
- Koya D et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC for type 2 diabetes. FASEB J. 2000; 14:439-447.
- Kikkawa R et al. Evidence for existence of polyol pathway in cultured rat mesangial cells. Diabetes. 2004; 36:240-243.
- Haneda M et al. Glucose inhibits myo-inositol uptake and reduces myo-inositol content in cultured rat glomerular mesangial cells. Metabolism. 2007; 39:40-45.
- Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988; 318:1315-1321.
- Browmlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414:813-820.
- Wei QQ. Insulin, insulin-degrading enzyme and amyloid-β peptide in Alzheimer’s disease:review and hypothesis. Neurobiology of aging. 2005; 23, 732-765.